Comparative Pharmacology
Head-to-head clinical analysis: EPSOLAY versus SARISOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPSOLAY versus SARISOL.
EPSOLAY vs SARISOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EPSOLAY (ivermectin) is an antiparasitic agent derived from avermectins. It acts by binding selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased permeability to chloride ions and hyperpolarization of the cell, resulting in paralysis and death of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA). Ivermectin does not readily cross the blood-brain barrier in humans and has minimal affinity for mammalian ligand-gated chloride channels.
Selective beta2-adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP levels, leading to bronchodilation.
Topical: Apply a pea-sized amount to the entire face once daily in the morning. Deliver 1-2 pumps to palm and apply to clean, dry face.
500 mg orally twice daily or 250 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2 to 4 minutes following intravenous administration; clinically, this rapid clearance limits systemic exposure and allows for localized effect.
12-15 hours; prolonged to 24-30 hours in severe hepatic impairment.
Primarily renal excretion of unchanged drug (approximately 60-70% of the absorbed dose) with hepatic metabolism accounting for the remainder; fecal excretion is minimal.
Renal (65% unchanged, 20% as metabolites), biliary/fecal (15%).
Category C
Category C
Topical Anti-acne Agent
Topical Anti-acne Agent